Bessor Pharma

Executive Summary

Bessor Pharma is a private, early-stage biotechnology company based in San Diego, developing novel therapeutics for cancer, immune-inflammatory, and other serious diseases. Founded in 2018, the company leverages a proprietary chemical synthesis platform that unlocks an untapped class of natural products with broad therapeutic potential. This platform could enable the discovery of first-in-class and best-in-class small molecule drugs, addressing high unmet medical needs across oncology and inflammation. Despite being in a preclinical stage with limited public disclosure, Bessor's focus on natural product-derived chemistry differentiates it from traditional small molecule approaches. The company's ability to advance its pipeline and secure partnerships will be critical for near-term value creation. Given the early stage and lack of disclosed milestones, the conviction score is moderate.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data for Lead Oncology Program30% success
• Q2 2026Series A Financing Round40% success
• H2 2026Platform Licensing or Collaboration Deal25% success